Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Assessing the reliability, accuracy, and utility of clinical abstraction methods from unstructured electronic health records (EHRs).

Katie Mo, Xifeng Wang, Kaitlynn Cunnea et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23311

e23311 Background: Real-world oncology data integrates structured and unstructured EHR-based information relating to clinical characteristics, treatment p...

A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.

Rana R. McKay, Wanling Xie, Archana Ajmera et al. Jun 01, 2025 pp. 5007-5007 10.1200/jco.2025.43.16_suppl.5007

5007 Background: Radium-223 is an α-emitting radioisotope which has improved overall survival (OS) in men with CRPC with B...

Metronomic therapy as a favorable independent factor for survival in high-risk oral cavity squamous cell carcinoma.

Hsueh-Ju Lu, Yen-Ting Lai, Yu-Wei Chiu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18022

e18022 Background: Oral cavity squamous cell carcinoma (OCSCC) is the largest subpopulation of head and neck squamous cell carcinoma in Taiwan. However, f...

Overall survival from the open label phase 2 trial of palbociclib in patients with advanced well differentiated/dedifferentiated liposarcoma.

Olayode Babatunde, Gary K. Schwartz, Mary Louise Keohan et al. Jun 01, 2025 pp. 11552-11552 10.1200/jco.2025.43.16_suppl.11552

11552 Background: Liposarcomas (LPS) are among the most common soft tissue sarcoma subtypes. Well-differentiated (WD) and dedifferentiated (DD) LPS are ch...

Empowering minority patients: A tailored education initiative for clinical trial awareness in thoracic oncology.

Tadana Angelica Vazquez Rothschuh, Keishla Marie Arce-Ruiz, Steve Sutton et al. Jun 01, 2025 pp. 1590-1590 10.1200/jco.2025.43.16_suppl.1590

1590 Background: Minority populations are underrepresented in clinical trials. Underrepresentation stems from multiple barriers that include restrictive e...

Association of an ancestry-specific variant near the <i>ESR1</i> gene with cancer risk and breast density in women of self-reported Hispanic ancestry.

Elisha Hughes, Allison W. Kurian, Eudora Hu et al. Jun 01, 2025 pp. 10513-10513 10.1200/jco.2025.43.16_suppl.10513

10513 Background: A single-nucleotide polymorphism (SNP), rs140068132, located in the 6q25 region near the ESR1 gene, is common in...

Development of second primary malignancies (SPMs) in head and neck cancer survivors stratified by receipt of radiation therapy (RT) and chemotherapy (CT).

Kriti Ahuja, Malak Alharbi, Vaishali Deenadayalan et al. Jun 01, 2025 pp. 11055-11055 10.1200/jco.2025.43.16_suppl.11055

11055 Background: Head and neck cancers (HNC) often require multimodality management for curative intent with surgery, radiation therapy (RT) with or with...

An open-label randomized trial of exercise ± creatine supplementation to augment the adaptations of exercise training in cancer survivors.

Darpan Patel, Rebecca Geck, Lisa Thibodeaux et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps12145

TPS12145 Background: Breast cancer survivors face a heightened risk of skeletal muscle wasting, which can be worsened by cancer treatments, adversely affe...

Indirect comparison of linvoseltamab versus elranatamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).

Sundar Jagannath, Hans C. Lee, Joshua Ryan Richter et al. Jun 01, 2025 pp. 7531-7531 10.1200/jco.2025.43.16_suppl.7531

7531 Background: In the absence of head-to-head trials comparing anti-BCMA×CD3 bispecific antibodies in TCE RRMM, this study used an unanchored matching-a...

Assessing the efficacy of ALK inhibitors in ALK-positive non-small cell lung cancer: A real-world data analysis.

Daniil Stroyakovskiy, Polina Shilo, Yana Akhmadiyarova et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20688

e20688 Background: Anaplastic lymphoma kinase (ALK) positive lung cancer represents a subtype with specific therapeutic targets. ALK inhibitors have signi...

Comprehensive clinicogenomic profiling of signet ring cell carcinoma across multiple organ sites.

Lawrence Wen Wu, Sara Wallam, Alexander Z. Wei et al. Jun 01, 2025 pp. 3138-3138 10.1200/jco.2025.43.16_suppl.3138

3138 Background: Signet ring cell carcinoma (SRCC) is a rare, aggressive histological subtype of adenocarcinoma that is associated with earlier age of ons...

NeoOPTIMIZE: Phase II trial of adaptive switching of neoadjuvant FOLFIRINOX (FFX) to gemcitabine/nab-paclitaxel (GA) resectable/borderline resectable (BR)/locally advanced (LA) pancreatic adenocarcinoma (PDAC).

Lyndsey Sandow, Justin Grenet, Adel Kardosh et al. Jun 01, 2025 pp. 4190-4190 10.1200/jco.2025.43.16_suppl.4190

4190 Background: Neoadjuvant chemotherapy (NAC) for localized PDAC may improve R0 resection. FFX and GA are used but lack of predictive biomarkers remains...

Real-world evidence of fruquintinib (Fruq) efficacy after regorafenib (Rego) and trifluridine–tipiracil (TAS-102) in refractory metastatic colorectal cancer (mCRC).

Oluseyi Abidoye, Anina Peersen, Jennah Bauernfeind et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23317

e23317 Background: mCRC poses significant challenges, particularly in patients (pts) who progress after multiple lines of therapy. Limited effective treat...

Whole genome-based circulating tumor DNA analysis as an ultrasensitive biomarker in pediatric sarcomas.

Claire Johns, Ajay Subramanian, Shaghayegh Soudi et al. Jun 01, 2025 pp. 10053-10053 10.1200/jco.2025.43.16_suppl.10053

10053 Background: Disease monitoring in pediatric sarcomas relies on invasive surgical biopsies and radiologic imaging, which often trail disease activity...

Identification and validation of potential diagnostic plasma biomarkers for diffuse gliomas by multiplex immunoassays.

Miyo K. Chatanaka, Lisa Avery, Mingyue Wang et al. Jun 01, 2025 pp. 2044-2044 10.1200/jco.2025.43.16_suppl.2044

2044 Background: Diffuse gliomas are aggressive malignant tumors with poor prognosis. The current standard of care includes measurement of molecular bioma...

Assessing the risk of cytokine release syndrome associated with the use of antineoplastic agents: A real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database (FAERS).

Adit Patel, Jahnavi Chaudhari, Mansi Mehta et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23359

e23359 Background: Cytokine Release Syndrome (CRS) is a severe immune-related toxicity commonly observed with immune-modulating therapies, particularly CA...

Treatment and lifestyle profiles of healthy aging survivors: A report from the Childhood Cancer Survivor Study.

Timothy James Daeeun Ohlsen, Kerry Ye, Cindy Im et al. Jun 01, 2025 pp. 10058-10058 10.1200/jco.2025.43.16_suppl.10058

10058 Background: Survivors of childhood cancer are at elevated risk for adverse health outcomes, but many maintain excellent health throughout adulthood....

The Hercules study: A prospective real-world evaluation of screening whole-body MRI (sWB-MRI) for multi-cancer detection and general preventive healthcare.

Yosef Chodakiewitz, Jeffrey Michael Venstrom, Daniel J. Durand et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps10626

TPS10626 Background: Cancer remains a leading cause of mortality, with major gaps in early detection contributing to later-stage diagnoses and poorer outc...

A platform to identify patients for cancer vaccine trials: The NHS England Cancer Vaccine Launch Pad (CVLP).

Victoria Goss, Nicole Keyworth, Dan Muller et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps11186

TPS11186 Background: The Cancer Vaccine Launch Pad (CVLP) was established in September 2023 to establish a process to increase the number of patients iden...

Trends in racial and regional disparities in breast cancer mortality among the female population in the United States: A retrospective database analysis from 1999-2020.

Maryam Masood, Khawaja Talha Aziz, Woo Joo Lee et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13824

e13824 Background: Breast cancer mortality in the United States has been decreasing since the last decade of the 20th century due to improvements in treat...

Impact of time to treatment initiation on overall survival for patients with osteosarcoma: A SEER database analysis.

Johnny Han, Lucia Chang, Richard Doan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13876

e13876 Background: Osteosarcoma is a primary bone tumor that predominantly affects children, adolescents, and young adults. It is typically managed with s...

Impact of immune checkpoint inhibitors on unplanned emergency department consultations in mNSCLC: More toxicities or lack of knowledge of their management.

Anthony Tarabay, Romane Fostier, Arnaud Pages et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24099

e24099 Background: Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of metastatic non-small cell Lung cancer (mNSCLC) treatment, alon...

Prognostic value of circulating tumor cells identified in the peripheral blood of patients with breast cancer treated with CDK4/6 inhibitors.

Sofia Agelaki, Maria A. Papadaki, Anna Stylianou et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15026

e15026 Background: CDK4/6 inhibitors represent an important treatment option for early and metastatic breast cancer (BC). The detection of circulating tum...

Long-term trends in gallbladder cancer incidence, mortality, and survival disparities: The impact of stage, age, ethnicity, and sex—Surveillance, Epidemiology, and End Results analysis.

Abat Khan, Aria Khan, Imran Khan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16182

e16182 Background: Gallbladder cancer (GBC) is a rare but aggressive malignancy, with survival outcomes influenced by disease stage, patient age, ethnicit...

Tislelizumab with anlotinib and chemotherapy for second-line treatment of pancreatic ductal adenocarcinoma: A phase II clinical trial.

Xuyuan Dong, Yinying Wu, Yangwei Fan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16394

e16394 Background: Advanced pancreatic ductal adenocarcinoma is a malignant tumor with poor prognosis. At present, chemotherapy is still the standard trea...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page